Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ILMN
STRONG BUYFLAGIllumina, Inc. · Healthcare · United States · $29.4B · Avg Vol: $359M/d
Illumina has strong quality Q77 and momentum M72 with a buyback retiring 2.47% of shares, but value at V27 is below the calibrated floor, so stage one fails. Insider selling is separately adverse.
COMPANY DESCRIPTION
Illumina, Inc. is the global leader in developing, manufacturing, and marketing integrated systems for large-scale analysis of genetic variation and function, providing sequencing and array-based instruments, reagents, and services. The company's formidable competitive moat stems from its proprietary sequencing technology, superior data quality, and extensive patent portfolio, which have established its platforms as the industry standard for genomic research and clinical applications worldwide. This dominant market position makes Illumina essential to advancements in precision medicine and biotechnology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.6B | 4.5B | 4.4B | 4.3B | -1.8% | 4.4B | 4.6B | 4.8B | 5.5% |
| EPS | -28.00 | -7.34 | -7.69 | 5.47 | — | 5.45 | 5.91 | 6.71 | 10.7% |
| Shares | 158.0M | 159.0M | 159.0M | 153.0M | -3.2% | 151.3M | — | — | — |
| Debt | 3.6B | 2.3B | 2.6B | 2.6B | -10.4% | 2.5B | — | — | — |
| Equity | 6.6B | 5.7B | 2.4B | 2.7B | -25.6% | — | — | — | — |
| Op CF | 392.0M | 478.0M | 837.0M | 1.1B | 40.1% | 1.1B | — | — | — |
| Inv CF | -591.0M | -231.0M | -178.0M | -55.0M | — | — | — | — | — |
| Fin CF | 1.0B | -1.2B | -570.0M | -744.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ILMN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ILMN | Illumina, Inc.(you) | $29.4B | 84 | STRONG BUY |
| DGX | Quest Diagnostics Incorporated | $25.1B | 89 | STRONG BUY |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| LH | Labcorp Holdings Inc. | $24.3B | 90 | STRONG BUY |
| MEDP | Medpace Holdings, Inc. | $16.8B | 78 | BUY |
| IQV | IQVIA Holdings Inc. | $34.7B | 67 | BUY |
| WAT | Waters Corporation | $36.8B | 65 | BUY |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 59 | HOLD |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
| RVTY | Revvity, Inc. | $12.3B | 65 | BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%